MedTrace Logo

Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL

NCT01914744 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2013-08-02

No results posted yet for this study

Summary

The aim of this study is to prove the superiority of entecavir over lamivudine for preventing the risk of hepatitis B virus reactivation in patients with non-Hodgkin lymphoma on CHOP/R-CHOP.

Conditions

Interventions

DRUG

Entecavir

entecavir 0.5 mg/day PO

DRUG

Lamivudine

lamivudine 100 mg/day PO

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Ye Guo, MD · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2015-12-31
Completion
2016-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01914744 on ClinicalTrials.gov